USING electronic health record data, researchers found that HbA1c levels declined by 1.5% among insulin degludec-treated patients compared with 1.2% in those treated with insulin glargine U300 over six months, according to a study of real-world data, presented at the American Diabetes Association Scientific Sessions in Orlando, Florida.
The difference was declared significant and researchers said this is the largest study using real-world data to demonstrate this variance.
CLICK HERE to access the abstract.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Sep 18
